Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition
Eli Lilly and Company logo. (PRNewsFoto)
INDIANAPOLIS, IN UNITED STATES
INDIANAPOLIS, Jan. 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company
(NYSE: LLY) today filed a Form 8-K/A with the U.S. Securities and Exchange
Commission (SEC) detailing the pro forma impact of the company's recently-
completed acquisition of ImClone Systems. The Form 8-K/A is available on the
SEC's website at www.sec.gov and the investor relations section of the
company's website at www.investor.lilly.com.
The content of the Form 8-K/A includes unaudited pro forma condensed
combined financial statements of Lilly and ImClone for the year ended December
31, 2007 and as of and for the nine months ended September 30, 2008. The
financial statements were prepared in accordance with accounting principles
generally accepted in the United States (GAAP).
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers - through medicines and information
- for some of the world's most urgent medical needs. Additional information
about Lilly is available at www.lilly.com. F-LLY
